Hepatitis C Treatment Insurance Claim Denied? How to Appeal

Hepatitis C is a curable disease. Modern direct-acting antiviral (DAA) medications — including sofosbuvir/ledipasvir (Harvoni), sofosbuvir/velpatasvir (Epclusa), and glecaprevir/pibrentasvir (Mavyret) — achieve cure rates exceeding 95% across most genotypes, with treatment courses of 8 to 12 weeks. The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) jointly recommend treatment for virtually all patients with chronic HCV infection, regardless of liver disease stage. Despite this authoritative clinical consensus, insurance denials for hepatitis C treatment remain common — driven by cost management rather than medicine. The good news: these denials are among the most legally and clinically reversible in insurance.

Why Insurers Deny Hepatitis C Treatment

Fibrosis stage restrictions. The most litigated denial type: insurers restrict DAA coverage to patients with advanced fibrosis (F3 or F4 on the METAVIR scale), denying treatment to those with F0–F2 disease. AASLD-IDSA guidelines at hcvguidelines.org explicitly recommend treatment for all patients with chronic HCV infection, without fibrosis stage limitation. Multiple federal courts have struck down fibrosis-based restrictions, finding them inconsistent with the ACA's essential health benefits mandate.

Sobriety and abstinence requirements. Some plans — particularly certain state Medicaid programs — impose 6- or 12-month abstinence requirements before approving DAA therapy. Federal courts and CMS guidance have found these requirements discriminatory under the Mental Health Parity and Addiction Equity Act (MHPAEA, 29 U.S.C. §1185a) because equivalent abstinence requirements are not applied to medical treatments for non-addiction conditions.

Specialist visit requirements. Plans require referral by or co-management with a hepatologist or infectious disease specialist before approving DAAs, creating access barriers in rural and underserved areas where specialists are unavailable. Primary care physicians routinely and safely prescribe DAAs.

Step therapy and formulary barriers. Insurers demand trials of specific DAA combinations despite clinical guidelines supporting multiple equivalent pangenotypic agents, or exclude newer agents from formulary to push older or less convenient regimens.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization documentation gaps. Nearly all DAA approvals require prior authorization. Denials frequently cite missing laboratory results — HCV RNA quantitation, genotype, fibrosis assessment — rather than clinical appropriateness. Completeness of documentation is critical.

How to Appeal a Hepatitis C Treatment Denial

Step 1: Obtain the Denial and the Insurer's Coverage Policy

Request your full denial letter, EOB)" class="auto-link">Explanation of Benefits (EOB), and a copy of the insurer's clinical coverage policy for hepatitis C treatment. The coverage policy reveals the exact criteria applied — and whether those criteria align with AASLD-IDSA guidelines or contradict them. Discrepancies between insurer criteria and professional guidelines are the foundation of your appeal.

Step 2: Gather Complete Clinical Documentation

Your appeal needs the treating physician's or gastroenterologist's letter of medical necessity referencing the AASLD-IDSA HCV guidance, plus the following specific laboratory results: HCV RNA quantitative viral load, HCV genotype, fibrosis assessment (FIB-4 score, FibroScan elastography result, or liver biopsy), and current liver function tests including ALT, AST, and a complete metabolic panel. If the denial cited missing labs, obtain and attach every result the coverage policy requires before resubmitting.

Step 3: Request a Peer-to-Peer Review Within Five Days

Ask your prescribing physician to request a peer-to-peer review with the insurer's medical director. Physicians speaking directly with reviewing physicians resolve many DAA denials before formal appeals are necessary — particularly when the denial rests on a documentation gap rather than a substantive coverage dispute. This is most effective within the first three to five days after denial.

Step 4: File the Internal Appeal Citing AASLD-IDSA Guidelines

Submit a written appeal that directly addresses every denial criterion. If denied for fibrosis stage, cite the AASLD-IDSA treatment-for-all recommendation and attach the relevant guideline excerpt (available at hcvguidelines.org). If denied for sobriety requirements, cite MHPAEA (29 U.S.C. §1185a) and note that abstinence requirements for HCV treatment are not applied to equivalent medical conditions. If your state has enacted legislation prohibiting fibrosis-based or sobriety-based restrictions — as New York, California, and Washington have — cite those statutes.

Step 5: Request Expedited Review if Clinically Urgent

If you have decompensated cirrhosis, portal hypertension, or are at imminent risk of liver failure, request an expedited internal appeal — plans must decide within 72 hours. Your physician's attestation of clinical urgency and documentation of liver disease severity (Child-Pugh score, MELD score, imaging findings) establishes the basis for expedited processing under federal regulations.

Step 6: Escalate to External Independent Review: Complete Guide" class="auto-link">External Review and Regulatory Complaints

If the internal appeal fails, file for independent external review immediately. External reviewers who are board-certified in hepatology or gastroenterology assess the clinical merits against current professional standards — not the insurer's internal criteria. Simultaneously, file complaints with your state insurance commissioner and, for ERISA employer plans, with the Department of Labor EBSA at dol.gov/agencies/ebsa.

What to Include in Your Appeal

• HCV RNA quantitative viral load and genotype results, plus fibrosis assessment (FIB-4, FibroScan, or biopsy) — the specific labs your plan's coverage policy requires
• Prescribing physician's letter of medical necessity citing AASLD-IDSA guidelines and explicitly recommending treatment regardless of fibrosis stage
• Printed excerpt from the AASLD-IDSA HCV guidance at hcvguidelines.org supporting treatment for all patients with chronic HCV infection
• State-specific law citations if your state has enacted prohibitions on fibrosis-based or sobriety-based coverage restrictions

Fight Back With ClaimBack

A hepatitis C denial is not a medical judgment — it is a cost-containment decision that contradicts the clinical consensus of every major hepatology and infectious disease organization. You have a curable disease and professional guidelines firmly on your side. ClaimBack generates a professional, evidence-backed appeal letter in 3 minutes, referencing the specific criteria your insurer used and the AASLD-IDSA guidelines that contradict them.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal